$2.57
0.00% today
Nasdaq, Apr 04, 09:14 pm CET
ISIN
US92859E1082
Symbol
VVOS

Vivos Therapeutics Inc Stock price

$2.57
-0.73 22.12% 1M
+0.07 2.80% 6M
-1.72 40.09% YTD
-0.44 14.62% 1Y
-49.93 95.10% 3Y
-222.18 98.86% 5Y
-222.18 98.86% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
+0.00 0.00%
ISIN
US92859E1082
Symbol
VVOS
Sector
Industry

Key metrics

Market capitalization $15.14m
Enterprise Value $10.39m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.69
P/S ratio (TTM) P/S ratio 1.01
P/B ratio (TTM) P/B ratio 1.90
Revenue growth (TTM) Revenue growth 8.91%
Revenue (TTM) Revenue $15.03m
EBIT (operating result TTM) EBIT $-11.17m
Free Cash Flow (TTM) Free Cash Flow $-13.26m
Cash position $6.26m
EPS (TTM) EPS $-3.10
P/S forward 0.84
EV/Sales forward 0.58
Short interest 4.25%
Show more

Is Vivos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Vivos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Vivos Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Vivos Therapeutics Inc:

Buy
100%

Financial data from Vivos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
15 15
9% 9%
100%
- Direct Costs 6.59 6.59
7% 7%
44%
8.44 8.44
10% 10%
56%
- Selling and Administrative Expenses 19 19
22% 22%
127%
- Research and Development Expense - -
-
-
-11 -11
36% 36%
-70%
- Depreciation and Amortization 0.58 0.58
6% 6%
4%
EBIT (Operating Income) EBIT -11 -11
35% 35%
-74%
Net Profit -11 -11
18% 18%
-74%

In millions USD.

Don't miss a Thing! We will send you all news about Vivos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vivos Therapeutics Inc Stock News

Neutral
Seeking Alpha
4 days ago
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman & CEO Conference Call Participants Guyn Kim - Water Tower Research Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vi...
Neutral
GlobeNewsWire
4 days ago
Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commerciali...
Neutral
GlobeNewsWire
7 days ago
LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate...
More Vivos Therapeutics Inc News

Company Profile

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Head office United States
CEO R. Huntsman
Employees 109
Founded 2016
Website www.vivos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today